SCHEMBL13698270

SCHEMBL13698270

CN1CB(c2ccc(Cl)c(Cl)c2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.42
SIGMAR1 Q99720 3/20 0.42
CYP1A2 P05177 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
THRB P10828 1/20 0.40
GAA P10253 1/20 0.39
LMNA P02545 2/20 0.38
OPRM1 P35372 1/20 0.38
SLC6A2 P23975 5/20 0.36
SLC6A4 P31645 5/20 0.36
SLC6A3 Q01959 4/20 0.36
KCNH2 Q12809 3/20 0.36
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 1/20 0.36
BCL2 P10415 1/20 0.36
MAPT P10636 1/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13698300 0.83 RAB9A (0.36) RAB9AGAASLC6A2ALDH1A1MAPT
SCHEMBL14136285 0.80 SIGMAR1 (0.50) CYP2D6SIGMAR1CYP1A2TMEM97
SCHEMBL13698294 0.79 SIGMAR1 (0.45) CYP2D6SIGMAR1CYP1A2TMEM97SMN1; SMN2
SCHEMBL13698268 0.78 SIGMAR1 (0.52) CYP2D6SIGMAR1CYP1A2TMEM97LMNA
SCHEMBL423400 0.64 MAPT (0.65) SMN1; SMN2RAB9AGAALMNAMAPK1
SCHEMBL623106 0.63 AHR (0.42) GAAALDH1A1MAPTALOX12
SCHEMBL29592391 0.63 AHR (0.42) GAAALDH1A1MAPTALOX12
SCHEMBL28721072 0.63 AHR (0.42) GAAALDH1A1MAPTALOX12
SCHEMBL13211554 0.61 SIGMAR1 (0.44) CYP2D6SIGMAR1CYP1A2TMEM97SMN1; SMN2
SCHEMBL13202506 0.60 SIGMAR1 (0.73) CYP2D6SIGMAR1CYP1A2TMEM97SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461196-B2 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders DOV PHARMACEUTICAL 2013-06-11 US disclosed
US-20120302619-A1 Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders OTSUKA AMERICA PHARMACEUTICAL, INC. 2012-11-29 US disclosed
US-20090233978-A1 Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders OTSUKA AMERICA PHARMACEUTICAL, INC. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302619-A1 Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders HTR3C, HTR1B, HTR2C CYP2D6 190/4885SIGMAR1 1402/4885CYP1A2 188/4885
US-20090233978-A1 Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders HTR3C, HTR1B, HTR2C CYP2D6 190/4885SIGMAR1 1402/4885CYP1A2 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.